Tempest Therapeutics Inc TPST
News
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
